강원 랜드 바카라 receives ‘A, A grade’ in technology evaluation…“Accelerates full-scale KOSDAQ listing plans”
Mirae Asset Securities named lead manager…Listing aimed at securities report submission within the year
[by Kang, In Hyo] 강원 랜드 바카라, a company specializing in the development of antibody-drug conjugates (ADCs), announced on June 25 that it has successfully passed the technology evaluation required for listing on the technology-specialized market.
강원 랜드 바카라 demonstrated its technological excellence and strong business potential by receiving A and A grades from two Korea Exchange-designated technology evaluation agencies. With this achievement, the company has fulfilled the main requirements for a technology-specialized listing and plans to initiate full-scale preparations for listing on the KOSDAQ market in H2 2025. Mirae Asset Securities is serving as the lead manager, and 강원 랜드 바카라 intends to submit a securities registration statement within the year.
강원 랜드 바카라 has established a differentiated ADC pipeline by integrating new target discovery, antibody development, intermediary research technologies, and its proprietary linker-payload platform, all centered on addressing unmet medical needs. Leveraging these integrated R&D capabilities, the company successfully signed a technology transfer agreement last year with U.S.-based Biohaven for ‘AMB302 (development code).’ More recently, 강원 랜드 바카라 further demonstrated its technological competitiveness by entering into co-development and licensing agreements with SK Plasma for AMB303.
In addition, 강원 랜드 바카라 successfully completed its pre-IPO (pre-listing investment) round ahead of schedule, securing a total investment of KRW 51.1 billion (approximately USD 37.7 million) from major Korean institutional investors, reflecting the market’s strong expectations in the company’s potential.
“This technology evaluation is the result of officially recognizing our technological perfection and global commercialization capabilities,” stated Her Nam-gu, CEO of 강원 랜드 바카라. “We will leverage the momentum gained through the listing process to accelerate our growth and leap forward as a global biotechnology company at the forefront of innovative anticancer drug development.”